Effect of “Double C” therapy combined with glibenclamide in the treatment of GDM patients and its influence on serum omentin-1 and VF levels

• Main Authors: Juan Li, Jian Guo, Chun-Xia Ren
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2019-03-01
• Series: Journal of Hainan Medical University
• Online Access: http://www.hnykdxxb.com/PDF/201906/14.pdf

Objective: To analyze the effect of “double C” therapy combined with glibenclamide in the treatment of GDM and its influence on serum omentin-1 and VF levels. Methods: 100 patients with GDM admitted to our hospital from January 2016 to May 2018 were randomly divided into observation group and control group. The control group was treated with routine treatment, while the observation group was treated with “double C” therapy combined with glibenclamide. Blood sugar level, cesarean section rate, premature delivery rate, pregnancyinduced hypertension rate, fetal distress and incidence of macrosomia were investigated. The levels of omentin-1 and VF in serum were measured. Results: The levels of HbA1c, FPG, 1 h PBG and 2 h PBG in blood of the two groups before delivery were significantly lower than those of the control group (P<0.05), and the levels of HbA1c, FPG, 1 h PBG and 2 h PBG in the observation group were significantly lower than those in the control group (P<0.05); the levels of omentin-1 and VF in the two groups before delivery were significantly higher (P<0.05), and the levels of omentin-1 in the observation group were significantly higher than those in the control group (P<0.05). After treatment, the rate of cesarean section, premature delivery, pregnancy-induced hypertension, fetal distress and macrosomia in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). Conclusions: The combination of double C therapy and glibenclamide can improve the curative effect of GDM and the levels of omentin-1 and VF in blood.